AndroGel Mechanism of Action: Full Pathway

Transdermal Absorption: How Testosterone Crosses the Skin Barrier

Testosterone in AndroGel's hydroalcoholic vehicle penetrates the stratum corneum through passive diffusion. The alcohol component evaporates within minutes, leaving a drug reservoir in the outer epidermal layers that releases testosterone over roughly 24 hours.

The stratum corneum is the rate-limiting barrier. Testosterone is a small (288.4 Da), moderately lipophilic molecule with a log P of approximately 3.3, giving it favorable partitioning into intercellular lipid lamellae 1. Gel excipients (ethanol, isopropyl myristate, carbomer) temporarily disrupt lamellar packing and increase permeability. Once past the stratum corneum, testosterone diffuses through the viable epidermis and enters dermal capillaries.

Roughly 10% of the applied dose reaches the bloodstream. The FDA-approved prescribing information for AndroGel 1% states that a 5 g daily dose (50 mg testosterone) delivers approximately 5 mg of bioavailable testosterone per day 2. This matches endogenous production rates in eugonadal men, which range from 3 to 10 mg daily. Serum testosterone begins rising within 30 minutes of application and reaches C_max at roughly 8 hours post-dose. Because the dermal reservoir sustains release, trough levels remain above baseline for a full 24-hour dosing interval.

Application site matters. Absorption from the shoulders and upper arms produces 20% to 30% higher serum levels than abdominal skin in some pharmacokinetic studies 3. Occlusion (covering the site with clothing) may increase absorption modestly, though formal occlusion studies with AndroGel are limited. Showering or swimming within 2 hours reduces drug delivery.

Systemic Distribution and Protein Binding

After entering the bloodstream, circulating testosterone binds to two main carrier proteins. The distribution phase determines how much hormone actually reaches target tissues.

Sex hormone-binding globulin (SHBG) binds approximately 44% of circulating testosterone with high affinity (K_d ~1 nM). Albumin binds another 50% with much lower affinity. Only 1% to 3% circulates as free (unbound) testosterone 4. The albumin-bound fraction dissociates readily at tissue capillary beds, so "bioavailable" testosterone (free plus albumin-bound) accounts for the physiologically active pool.

This is a critical pharmacological distinction. Patients with elevated SHBG (common in aging, liver disease, or hyperthyroidism) may have total testosterone in the reference range yet still present with hypogonadal symptoms because their free fraction is low. The 2018 Endocrine Society Clinical Practice Guideline recommends "measurement of total testosterone as the initial diagnostic test" but specifies that "in men in whom total testosterone is near the lower limit, measurement of free or bioavailable testosterone may be helpful" 4.

Testosterone distributes widely. It crosses the blood-brain barrier (accounting for CNS effects on mood and cognition), enters skeletal muscle satellite cells, accumulates in prostate epithelium, and reaches bone marrow progenitor cells. The volume of distribution is large, estimated at 590 L for endogenous testosterone. AndroGel-delivered testosterone follows the same distribution pattern as endogenous hormone once it is in circulation.

Intracellular Metabolism: 5α-Reductase and Aromatase Pathways

Testosterone itself is active, but two enzyme families convert it into metabolites with distinct receptor profiles. This branching is where much of the tissue-specific pharmacology originates.

5α-reductase conversion. In prostate, skin, and hair follicle cells, the enzyme 5α-reductase (type II predominating in prostate; type I in skin) irreversibly converts testosterone to dihydrotestosterone (DHT). DHT binds the androgen receptor with roughly 2 to 3 times the affinity of testosterone and dissociates more slowly, making it the dominant androgen in these tissues 5. In men using AndroGel 1% at the 5 g/day dose, serum DHT levels rise proportionally, and the DHT:testosterone ratio typically remains within the physiological range of 1:10 to 1:12 2.

Aromatase conversion. In adipose tissue, brain, and bone, the cytochrome P450 enzyme aromatase (CYP19A1) converts testosterone to 17β-estradiol. This estrogen signal is not a side effect. It is required for epiphyseal closure in younger men, maintenance of bone mineral density in older men, and modulation of libido through central pathways 6. Men with aromatase deficiency develop osteoporosis despite normal testosterone, confirming estradiol's independent role in male skeletal health. In TRT patients, clinicians monitor estradiol alongside testosterone to verify that the aromatase pathway is producing, but not overproducing, estrogen.

A third metabolic route, hepatic oxidation and glucuronidation, clears testosterone. Because AndroGel bypasses first-pass hepatic metabolism (unlike oral methyltestosterone), the liver receives physiological rather than supraphysiological testosterone concentrations. This is the primary safety advantage of transdermal delivery over oral 17α-alkylated androgens.

Androgen Receptor Activation and Gene Transcription

The molecular endpoint of AndroGel therapy is activation of the androgen receptor (AR), a type I nuclear receptor encoded on chromosome Xq11-12. This step converts a circulating hormone signal into changes in protein expression.

Free testosterone (or DHT) diffuses across the target cell membrane and binds the AR in the cytoplasm. Ligand binding triggers a conformational change: heat shock proteins (HSP90, HSP70) dissociate from the receptor, exposing a nuclear localization signal 7. The ligand-AR complex dimerizes and translocates into the nucleus.

Inside the nucleus, the AR dimer binds androgen response elements (AREs), specific DNA sequences in the promoter regions of target genes. AR then recruits coactivator proteins (SRC-1, SRC-3, p300/CBP) that remodel chromatin and initiate RNA polymerase II transcription. The result is tissue-specific changes in protein synthesis.

Downstream gene targets vary by cell type:

• Skeletal muscle: AR activation upregulates IGF-1, myogenin, and myosin heavy chain genes, increasing muscle protein accretion. In the TTrials (N=790), men aged 65 and older who applied testosterone gel daily for 12 months gained a mean 1.28 kg of lean body mass compared with placebo (P<0.001) 8.
• Bone: AR and estrogen receptor (ER) signaling together suppress osteoclast activity and stimulate osteoblast differentiation. The TTrials bone substudy showed a significant increase in volumetric bone mineral density at the spine (7.5%) and hip trabecular compartment after 12 months of testosterone gel treatment 9.
• Erythropoiesis: Testosterone stimulates renal erythropoietin production and directly enhances erythroid progenitor proliferation, raising hemoglobin. The TTrials reported a mean hemoglobin increase of 1.0 g/dL in the testosterone group versus 0.2 g/dL in placebo 8.
• CNS: AR activation in limbic structures modulates sexual desire and spatial cognition. TTrials participants in the sexual function substudy reported significant improvements in sexual activity and desire scores 8.

HPG Axis Negative Feedback: Why Endogenous Production Shuts Down

Exogenous testosterone from AndroGel suppresses the hypothalamic-pituitary-gonadal (HPG) axis. This is a predictable pharmacological consequence, not a complication, but it has clinical implications for fertility.

Testosterone and its metabolite estradiol act on hypothalamic GnRH neurons and anterior pituitary gonadotrophs to reduce secretion of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) 10. LH is the primary driver of Leydig cell testosterone synthesis. FSH supports Sertoli cell function and spermatogenesis. When exogenous testosterone provides a continuous negative feedback signal, both LH and FSH fall to low or undetectable levels within weeks.

The clinical consequence: spermatogenesis declines. Intratesticular testosterone concentrations, normally 40 to 100 times higher than serum levels, drop sharply when Leydig cells stop producing. This is why the Endocrine Society guideline states that "testosterone therapy should not be used in men who desire fertility in the near term" 4. Recovery of spermatogenesis after discontinuation is variable, often requiring 6 to 18 months, and is not guaranteed.

For hypogonadal men not seeking fertility, the suppression of LH and FSH is clinically neutral. The exogenous gel replaces the testosterone that Leydig cells would otherwise produce. Monitoring serum testosterone (trough level, drawn in the morning before the day's application) confirms that the replacement dose is adequate.

Pharmacokinetic Profile: Steady State and Dose Titration

AndroGel's pharmacokinetics differ markedly from injectable testosterone esters. Understanding the absorption and clearance curve explains why dosing adjustments follow a specific rhythm.

Peak serum testosterone occurs approximately 8 hours after application, with trough levels at 24 hours 2. The peak-to-trough ratio is roughly 1.5:1 for AndroGel 1%, which is far flatter than the 3:1 to 4:1 swings seen with biweekly intramuscular testosterone cypionate injections. This flatter profile mimics the mild diurnal rhythm of endogenous testosterone (highest in early morning, lowest in late evening) more closely than bolus injections do.

Steady state is reached within 24 to 48 hours. This is fast. Injectable testosterone enanthate or cypionate requires 4 to 6 weeks to reach stable trough levels due to the slow release from the oil depot. The gel's rapid steady state allows clinicians to check a serum testosterone level after just 2 to 4 weeks of a given dose and adjust accordingly.

The standard titration protocol starts at 5 g daily (50 mg testosterone for the 1% formulation). If trough serum testosterone remains below 400 ng/dL after 2 to 4 weeks, the dose can be increased to 7.5 g or 10 g daily. If levels exceed 1,000 ng/dL or if hematocrit rises above 54%, the dose should be reduced 4. Dr. Shalender Bhasin, lead author of the 2018 Endocrine Society guideline, noted: "The goal of testosterone therapy is to restore serum testosterone concentrations to the normal range for young men, typically 400 to 700 ng/dL at trough" 4.

The elimination half-life of testosterone delivered by gel is effectively determined by the absorption rate from the skin depot, not by the intrinsic plasma half-life (10 to 100 minutes for free testosterone). Once the gel reservoir is depleted or washed off, serum levels decline over approximately 24 to 48 hours.

Clinical Validation: Evidence From the Testosterone Trials

The Testosterone Trials (TTrials) remain the largest placebo-controlled evidence base for topical testosterone gel in older hypogonadal men. Published in the New England Journal of Medicine in 2016, these coordinated trials enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism 8.

Participants applied testosterone gel (AndroGel 1%) or placebo daily for 12 months. The dose was titrated to achieve serum testosterone between 400 and 800 ng/dL. Mean serum testosterone rose from approximately 234 ng/dL at baseline to 565 ng/dL at 3 months in the treatment arm and remained stable through month 12.

Three primary outcomes showed benefit. Sexual function improved significantly: sexual activity scores increased by 0.58 activities per day versus 0.07 in placebo (P<0.001). Physical function showed a modest but statistically significant improvement in the 6-minute walk test. Vitality scores (measured by the FACIT-Fatigue scale) improved but did not reach the pre-specified threshold for clinical significance.

Dr. Peter Snyder, the principal investigator, stated: "Raising testosterone levels in older men to the mid-normal range for young men improved all aspects of sexual function, improved mood and depressive symptoms, and increased walking distance" 8.

Safety signals in the TTrials included a greater increase in coronary artery calcium score in the testosterone group (a finding that requires longer-term cardiovascular outcome data to interpret) and the expected rise in hematocrit. There were no significant differences in major adverse cardiovascular events during the 12-month treatment period.

Tissue-Level Effects: Connecting Receptor Activation to Patient Outcomes

The molecular pathway from AR activation to clinical benefit spans hours to months, depending on the tissue. A single dosing event triggers gene transcription within hours, but phenotypic changes accumulate over weeks to months.

Erythropoiesis responds within 3 to 6 months. The mechanism runs through both direct AR stimulation of erythroid progenitors and indirect stimulation via renal erythropoietin 11. Hematocrit monitoring at 3, 6, and 12 months is standard of care. A hematocrit above 54% triggers dose reduction or temporary discontinuation because of increased blood viscosity and thrombotic risk.

Muscle protein synthesis ramps up within the first week of restored testosterone levels. Measurable lean mass gains appear by 3 to 6 months. Fat mass reduction occurs on a similar timeline, primarily through AR-mediated suppression of adipocyte differentiation and lipolysis enhancement.

Bone remodeling is the slowest responder. Increases in bone mineral density require 6 to 12 months of sustained eugonadal testosterone levels to become detectable on DXA. The TTrials bone substudy confirmed increases in estimated bone strength at both the spine and hip at 12 months 9.

Mood and cognitive effects vary. Some patients report improved energy and reduced depressive symptoms within 3 to 6 weeks. The TTrials vitality substudy found a statistically significant but clinically modest improvement in energy levels by month 3 8.

How AndroGel Compares Mechanistically to Other TRT Routes

The testosterone molecule is identical regardless of delivery route. What changes across formulations is the pharmacokinetic profile, which affects how the AR signal is delivered to tissues over time.

Intramuscular testosterone cypionate (200 mg every 2 weeks) produces a supraphysiological peak (often exceeding 1,200 ng/dL) 24 to 48 hours post-injection, followed by a steady decline to sub-therapeutic levels before the next dose 12. This roller-coaster pattern means AR activation intensity fluctuates widely across the dosing interval. Patients often report mood swings, energy dips before injection day, and acne flares after injection day.

AndroGel produces a much flatter curve. Peak-to-trough variation stays within approximately 50% of the mean, more closely mimicking physiological diurnal variation. This translates to steadier AR occupancy in target tissues and, for many patients, more stable symptom control.

Subcutaneous testosterone pellets (Testopel) provide the flattest curve, with slow, consistent release over 3 to 6 months. Nasal testosterone (Natesto) produces a sharp spike three times daily with rapid clearance, potentially preserving more gonadotropin signaling than continuous-release formulations 13.

Each route activates the same receptor. The clinical difference is duration and consistency of AR occupancy per dosing interval.